tined for the basolateral membrane. In MDCK cells, components of the exocyst, namely
Sec 6/8 [because early work was largely performed with antibodies to Sec 6 and Sec 8, the
mammalian exocyst is often called the Sec 6/8 complex (Hsu et al. 1999)], are rapidly re-
cruited from the cytosol to sites of cell–cell contact upon initiation of calcium-dependent
cell–cell adhesion (see section entitled “Genesis of cell polarity,” below). As polarity de-
velops, the complex becomes restricted to a zone near the junctional complex on the later-
al membrane (Grindstaff et al. 1998b). In addition, functional studies demonstrated that
neutralizing antibodies to Sec 8 partially inhibit the delivery of LDL receptors to the baso-
lateral membrane but have no effect on apical membrane-destined cargo in the streptoly-
sin-O permeabilized polarized MDCK cell model (Grindstaff et al. 1998b). Taken togeth-
er, these observations provided key evidence for the involvement of the Sec 6/8 complex
as an active site of insertion for basolateral membrane-destined transport vesicles. Recent
live-cell imaging analysis of post-Golgi trafficking vesicles in MDCK cells indicated that
plasma membrane fusion events of vesicles containing GFP-tagged LDLR, may in fact,
occur along the lateral membrane at sites that are nearly, albeit not perfectly, coincident
with Sec 6 localization (and syntaxin 4; see section entitled “Fusion”) (Kreitzer et al.
2003). This new observation reinforces the concept that the Sec 6/8 complex may be in-
volved in basolateral membrane docking.
Other components of the exocyst have been implicated in polarized basolateral mem-
brane trafficking. For instance, Sec 10 colocalizes with Sec 6/8 (Lipschutz et al. 2000) and
Exo 70 is recruited into the Sec 6/8 complex at cell–cell contact points in polarizing
MDCK cells (Matern et al. 2001). Interestingly, overexpression of exogenous Sec 10 se-
lectively enhances basolateral transport in MDCK cells (Lipschutz et al. 2000).
Our present understanding about how the exocyst might orchestrate polarized delivery,
tethering, and/or docking of exocytic vesicles at the lateral membrane in mammalian epi-
thelial cells has been shaped from mechanistic studies on the yeast exocyst. In yeast, as-
sembly of the exocyst complex is tightly controlled by a specific secretory vesicle-associ-
ated Rab GTPase, called Sec 4 (see section entitled “Rab”) (Guo et al. 1999). Docking, on
the other hand, is specified by Rho-dependent localization of Sec 3 at the bud tip (Finger
et al. 1998). In this scheme, the active, GTP-bound, form of Sec 4 directly interacts with a
component of the exocyst, Sec 15. This protein–protein interaction then initiates assembly
of the entire exocyst complex, and consequently Sec 4p on the secretory vesicle surface
becomes indirectly tethered to Sec 3 on the cell surface (Guo et al. 1999). Intriguingly, the
most likely mammalian ortholog of Sec 4, Rab 8, has been strongly implicated in basolat-
eral membrane trafficking (Huber et al. 1993; Ang et al. 2003) (see sections entitled
“Rab” and “Adaptin”), suggesting a parallel between yeast and mammalian epithelia. Fur-
ther studies are required to determine if Rab 8 actually interacts with mammalian Sec 15p
to orchestrate exocyst assembly.
Although there may be a number of mechanistic parallels, the mammalian exocyst in
epithelial cells appears to be different from yeast in several important respects. First, intra-
cellular localization of the Sec 6/8 complex may be highly dynamic. For instance, maneu-
vers that block trafficking in the secretory pathway, such as low temperature or Brefeldin
A treatment, cause Sec 6/8 to accumulate near the TGN (Yeaman et al. 2001). These ob-
servations suggest that localization of Sec 6/8 in mammalian epithelia depends on contin-
uous exocytic vesicle trafficking. Second, in contrast to yeast, the mammalian Sec 3p, is
neither a Rho effector nor does it act as a spatial landmark for exocytosis on the lateral
membrane of mammalian epithelia (Matern et al. 2001). Exactly how the complex associ-
76 Rev Physiol Biochem Pharmacol (2005) 153:47–99